Biologic viral safety is entering a new phase. Updated global ICH guidance is reshaping how manufacturers approach risk based controls, modern analytics and manufacturing innovation. In this PharmTech feature, John M. e...
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
Business leaders call on corporate Ireland to support global vaccine rollout
In this article, CFO Brendan Brennan discusses the responsibility of CROs in the fight against COVID-19, particularly by helping the most vulnerable populations gain access to vaccines and treatments.
-
A multifaceted global approach to addressing antimicrobial resistance
Dr. Caroline Forkin, VP Clinical Research Services, considers the best approach to address antimicrobial resistance.
This article is taken from European Biopharmaceutical Review October 2021, pages 70-73. Samedan Ltd
-
Pharma’s coming home
Seth Nelson, Senior Director of Patient Recruitment and Clinical Research Services, provides expert commentary on patient centricity during the pandemic.
-
A trusted partner for clinical development
ICON CEO Steve Cutler chats with Newsweek, on ICON’s role in the development of much needed medicines. The interview (page 12 of PDF) is part of a special report on Ireland.
-
Global collaboration: Irish company ICON on scaling up COVID-19 vaccine trials
An interview in which Steve Cutler gives a short overview of ICON and describes the company’s role in the Pfizer/BioNTech trial, explaining how the FDA played a critical role in expediting regulatory approvals.
-
The effect of Covid-19 solutions on the clinical trials process
Shelley McLendon, VP of Project Management, Vaccines and Infectious Diseases, outlines best practices that can keep trials running at optimal speed and efficiency, and the benefits of adopting a strategic partnership.
-
-
COVID-19 trial of alternating vaccines begins in the UK
Recruitment has begun in the UK for a world-first study to investigate whether using different COVID-19 vaccines for first and second doses is as effective as using the same type of vaccine for both. ICON’s Dr Garrett provides commentary.
-
No10 launches world's first trial into whether mixing and matching coronavirus vaccines can enhance protection
ICON's Dr. Garrett comments on the UK government's new 'Com-Cov' study of over 800 patients, designed to test mixing doses of the Oxford and Pfizer COVID-19 vaccines, as well as different intervals between doses.
-
Irish pharma group ICON carried out trial of Pfizer-BioNTech vaccine
The Irish Times discusses how ICON carried out the Pfizer-BioNTech vaccine trials.
